secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093314
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024
--------------------------------------------------------------------------------

- Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.
- CLN-978 (CD19xCD3 T cell engager) IND for SLE on track for Q3 2024; pursuing RA with FAU Erlangen & Università Cattolica.
- CLN-619 combo data at ASCO showed objective responses in oncogenic mutation NSCLC; expansion cohorts added.
- Positive initial zipalertinib data from REZILIENT1 study; ESMO presentation planned.
- Discontinued CLN-418; returned rights to Harbour BioMed. Oversubscribed PIPE raised $280M in April.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024093314/0000950170-24-093314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024093314/cgem-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer